Semiclassical theory of quasiparticles in the superconducting state

We have developed a semiclassical approach to solving the Bogoliubov - de Gennes equations for superconductors. It is based on the study of classical orbits governed by an effective Hamiltonian corresponding to the quasiparticles in the superconducting state and includes an account of the Bohr-Sommerfeld quantisation rule, the Maslov index, torus quantisation, topological phases arising from lines of phase singularities (vortices), and semiclassical wave functions for multi-dimensional systems. The method is illustrated by studying the problem of an SNS junction and a single vortex.Comment: 74 pages, 19 figures, 3 tables. Submitted to Academic Press for possible publicatio

Precision Pion-Proton Elastic Differential Cross Sections at Energies Spanning the Delta Resonance

A precision measurement of absolute pi+p and pi-p elastic differential cross sections at incident pion laboratory kinetic energies from T_pi= 141.15 to 267.3 MeV is described. Data were obtained detecting the scattered pion and recoil proton in coincidence at 12 laboratory pion angles from 55 to 155 degrees for pi+p, and six angles from 60 to 155 degrees for pi-p. Single arm measurements were also obtained for pi+p energies up to 218.1 MeV, with the scattered pi+ detected at six angles from 20 to 70 degrees. A flat-walled, super-cooled liquid hydrogen target as well as solid CH2 targets were used. The data are characterized by small uncertainties, ~1-2% statistical and ~1-1.5% normalization. The reliability of the cross section results was ensured by carrying out the measurements under a variety of experimental conditions to identify and quantify the sources of instrumental uncertainty. Our lowest and highest energy data are consistent with overlapping results from TRIUMF and LAMPF. In general, the Virginia Polytechnic Institute SM95 partial wave analysis solution describes our data well, but the older Karlsruhe-Helsinki PWA solution KH80 does not.Comment: 39 pages, 22 figures (some with quality reduced to satisfy ArXiv requirements. Contact M.M. Pavan for originals). Submitted to Physical Review

Nuclei in Strongly Magnetised Neutron Star Crusts

We discuss the ground state properties of matter in outer and inner crusts of neutron stars under the influence of strong magnetic fields. In particular, we demonstrate the effects of Landau quantization of electrons on compositions of neutron star crusts. First we revisit the sequence of nuclei and the equation of state of the outer crust adopting the Baym, Pethick and Sutherland (BPS) model in the presence of strong magnetic fields and most recent versions of the theoretical and experimental nuclear mass tables. Next we deal with nuclei in the inner crust. Nuclei which are arranged in a lattice, are immersed in a nucleonic gas as well as a uniform background of electrons in the inner crust. The Wigner-Seitz approximation is adopted in this calculation and each lattice volume is replaced by a spherical cell. The coexistence of two phases of nuclear matter - liquid and gas, is considered in this case. We obtain the equilibrium nucleus corresponding to each baryon density by minimizing the free energy of the cell. We perform this calculation using Skyrme nucleon-nucleon interaction with different parameter sets. We find nuclei with larger mass and charge numbers in the inner crust in the presence of strong magnetic fields than those of the zero field case for all nucleon-nucleon interactions considered here. However, SLy4 interaction has dramatic effects on the proton fraction as well as masses and charges of nuclei. This may be attributed to the behaviour of symmetry energy with density in the sub-saturation density regime. Further we discuss the implications of our results to shear mode oscillations of magnetars.Comment: presented in "Exciting Physics Symposium" held in Makutsi, South Africa in November, 2011 and to be published in a book by Springer Verla

Habitable Zones in the Universe

Habitability varies dramatically with location and time in the universe. This was recognized centuries ago, but it was only in the last few decades that astronomers began to systematize the study of habitability. The introduction of the concept of the habitable zone was key to progress in this area. The habitable zone concept was first applied to the space around a star, now called the Circumstellar Habitable Zone. Recently, other, vastly broader, habitable zones have been proposed. We review the historical development of the concept of habitable zones and the present state of the research. We also suggest ways to make progress on each of the habitable zones and to unify them into a single concept encompassing the entire universe.Comment: 71 pages, 3 figures, 1 table; to be published in Origins of Life and Evolution of Biospheres; table slightly revise

Physics of Neutron Star Crusts

The physics of neutron star crusts is vast, involving many different research fields, from nuclear and condensed matter physics to general relativity. This review summarizes the progress, which has been achieved over the last few years, in modeling neutron star crusts, both at the microscopic and macroscopic levels. The confrontation of these theoretical models with observations is also briefly discussed.Comment: 182 pages, published version available at <http://www.livingreviews.org/lrr-2008-10

Transit amplifying cells coordinate mouse incisor mesenchymal stem cell activation

10.1038/s41467-019-11611-0Nature Communications101359

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication